Studies on 1-(2-phenethyl)-4-(N-propionylanilino)piperidine (fentanyl) and related compounds VII. Quantification of α-methylfentanyl metabolites excreted in rat urine
Received 30 April 2009; received in revised form 5 November 2009; accepted 17 November 2009. published online 14 December 2009.
Abstract
The use of chemically modified controlled drugs, called designer drugs, is widespread internationally. In the 1980s, the dominant drugs of abuse were modifications of fentanyl formed by methylation of both the α-position of its phenethyl group (α-methylfentanyl) and the 3-position of its piperidine ring (3-methylfentanyl). Numerous analytical methods for fentanyl and its analogues, and many studies of its metabolism and major metabolites, have been reported. However, minor metabolites that reflected injection of the original compound were not included in these studies. Recently, structures of four novel and minor metabolites that reflect α-methylfentanyl have been reported. This study reports excretion amounts of these compounds for 96h following peroral injection to rats of 3mg/day and urine collection every 24h. Major metabolites were the same as for fentanyl, with approximately 24% of α-methylfentanyl excreted as nor-fentanyl and 15% as ω, ω-1 hydroxypropiony nor-fentanyl up to 72h post-injection. The novel metabolites were completely excreted within 48h of injection and composed 2–3% of the total metabolite pool. The major metabolite nor-fentanyl was detected up to 72h after injection.